Oncology News

Patients with hepatocellular carcinoma and hepatitis C were less likely to achieve sustained virologic response while receiving direct-acting antiviral therapy compared with patients without HCC, according to results of a retrospective study.

Hepatocellular carcinoma was linked to patients with hepatitis B in South America, particularly those younger than 50 years, according to results of a retrospective, multi-center study.

Researchers found evidence suggesting that tumor sizes at the margins of hepatocellular carcinoma-related transplantation criteria may be subject to inaccurate reporting, according to results of a recently published study.

The use of capecitabine as adjuvant therapy significantly extended survival of patients with biliary tract cancer, according to results of the BILCAP clinical trial scheduled for presentation at the ASCO Annual Meeting.

Nivolumab appeared safe and effective in patients with advanced liver cancer who did not respond to sorafenib, according to results from the CheckMate 040 study presented at the International Liver Congress 2017.

The FDA expanded the approval of regorafenib to include the treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib.

Tiziana announced approval in Israel of a phase 2 clinical trial to test the safety of milciclib, a novel inhibitor of cell cycle dependent kinases, in patients with refractory hepatocellular carcinoma, according to a press release.

AMSTERDAM — Selective internal radiation therapy failed to best Nexavar in overall survival but did yield improvements in other parameters, including quality of life, in patients with hepatocellular carcinoma, according to data presented at the International Liver Congress.

AMSTERDAM — Approximately one-third of children under 18 years in the United Kingdom with hepatitis C developed serious long-term liver disease, according to data presented at the International Liver Congress.

AMSTERDAM — Curing patients with cirrhosis of hepatitis C virus could alter the inflammatory milieu and have an impact on the way CD8+ T-cells surveil potential carcinoma, according to data presented at the International Liver Congress.